These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23973014)

  • 1. Zoophilia and Parkinson's disease.
    Almeida KJ; de Oliveira Filho MC; Lopes Nery PC; Guimarães Silva JS; Campos Sousa RN
    Parkinsonism Relat Disord; 2013 Dec; 19(12):1167-8. PubMed ID: 23973014
    [No Abstract]   [Full Text] [Related]  

  • 2. Hyperthyroidism "masked" the levodopa response in newly diagnosed Parkinson's disease patients.
    Prakash KM; Kek PC
    Parkinsonism Relat Disord; 2010 Dec; 16(10):691-2. PubMed ID: 20729126
    [No Abstract]   [Full Text] [Related]  

  • 3. Levodopa dependence and abuse in Parkinson's disease.
    Spigset O; von Schéele C
    Pharmacotherapy; 1997; 17(5):1027-30. PubMed ID: 9324193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Evidence is insufficient to show that combined treatment increases mortality.
    Aaltonen H; Kilkku O; Heinonen E; Mäki-Ikola O
    BMJ; 1998 Dec; 317(7172):1586-7. PubMed ID: 9890764
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug therapy of Parkinson's disease].
    Zhou XD
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of adding selegiline to levodopa in early, mild Parkinson's disease. Formal systematic review of data on patients in all relevant trials is required.
    Counsell C
    BMJ; 1998 Dec; 317(7172):1586. PubMed ID: 9836669
    [No Abstract]   [Full Text] [Related]  

  • 7. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
    Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH
    Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
    Dessibourg CA; Gachoud JP
    Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future approaches to therapy.
    Birkmayer W; Birkmayer JD
    Adv Neurol; 1987; 45():511-2. PubMed ID: 3103393
    [No Abstract]   [Full Text] [Related]  

  • 10. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS; Fazzini E; Volkow ND
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract]   [Full Text] [Related]  

  • 11. An add-on study of selegiline to Madopar in the treatment of parkinsonian patients with dose-related fluctuations: comparison between Jumexal and Parkryl.
    Shan DE; Yeh SI
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Oct; 58(4):264-8. PubMed ID: 8994331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Motor fluctuations in Parkinson's disease: the "New frontier" of therapeutic success. A Roche Laboratory seminar].
    d'Anglejan Chatillon J
    Rev Prat; 1989 Mar; 39(8):689-90. PubMed ID: 2727575
    [No Abstract]   [Full Text] [Related]  

  • 13. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficiency of new forms of madopar in Parkinson's disease].
    Vendrova MI; Sadekov RA; Golubev VL
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):46-8. PubMed ID: 11195538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deprenyl in Parkinson's disease.
    Korczyn AD; Nisipeanu P
    Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
    [No Abstract]   [Full Text] [Related]  

  • 16. Pramipexole-related chronic lower limb oedema in a patient with Parkinson's disease.
    Zavala JA; Munhoz RP; Teive HA
    J Clin Neurosci; 2012 Sep; 19(9):1298-9. PubMed ID: 22721884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction in Parkinson's disease therapy improved punding but not feeling of presence.
    Aquino CC; Celso de Castro P; Doná F; Medeiros L; Silva SM; Borges V; Ferraz HB
    J Neuropsychiatry Clin Neurosci; 2013; 25(3):E43-4. PubMed ID: 24026740
    [No Abstract]   [Full Text] [Related]  

  • 18. (-)Deprenyl in the treatment of decompensated Parkinson's disease.
    Csanda E; Tárczy M; Takáts A
    J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moderate Parkinson's disease. Strategies for maximizing treatment.
    Silverstein PM
    Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.
    Contin M; Riva R; Martinelli P; Cortelli P; Albani F; Baruzzi A
    Clin Neuropharmacol; 1999; 22(6):351-5. PubMed ID: 10626097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.